Durability of Evoked Compound Action Potential (ECAP)-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) in a Real-World European Chronic Pain Population.

Autor: Nijhuis H; St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, Netherlands. h.nijhuis@antoniusziekenhuis.nl., Kallewaard JW; Rijnstate Hospital, Velp, Netherlands.; Erasmus University Medical Center, Rotterdam, Netherlands., van de Minkelis J; Elisabeth-Tweesteden Hospital, Tilburg, Netherlands., Hofsté WJ; St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, Netherlands., Elzinga L; Bravis Hospital, Roosendaal, Netherlands., Armstrong P; York and Scarborough NHS Hospital Trust, York, UK., Gültuna I; Albert Schweitzer Hospital, Zwijndrecht, Netherlands., Almac E; Alrijne Hospital, Leiderdorp, Netherlands., Baranidharan G; Leeds Teaching Hospital, Leeds, UK., Nikolic S; St. Bartholomew's Hospital, London, UK., Gulve A; James Cook University Hospital, Middlesbrough, UK., Vesper J; Heinrich-Heine University Düsseldorf, Düsseldorf, Germany., Dietz BE; Saluda Medical Europe Ltd, Harrogate, UK., Mugan D; Saluda Medical Europe Ltd, Harrogate, UK., Huygen FJPM; Academisch Universitair Medisch Centrum, Amsterdam, Netherlands.
Jazyk: angličtina
Zdroj: Pain and therapy [Pain Ther] 2024 Oct; Vol. 13 (5), pp. 1119-1136. Date of Electronic Publication: 2024 Jul 02.
DOI: 10.1007/s40122-024-00628-z
Abstrakt: Introduction: Closed-loop spinal cord stimulation (CL-SCS) is a recently introduced system that records evoked compound action potentials (ECAPs) from the spinal cord elicited by each stimulation pulse and uses this information to automatically adjust the stimulation strength in real time, known as ECAP-controlled SCS. This innovative system compensates for fluctuations in the distance between the epidural leads and the spinal cord by maintaining the neural response (ECAP) at a predetermined target level. This data collection study was designed to assess the performance of the first CL-SCS system in a real-world setting under normal conditions of use in multiple European centers. The study analyzes and presents clinical outcomes and electrophysiological and device data and compares these findings with those reported in earlier pre-market studies of the same system.
Methods: This prospective, multicenter, observational study was conducted in 13 European centers and aimed to gather electrophysiological and device data. The study focused on the real-world application of this system in treating chronic pain affecting the trunk and/or limbs, adhering to standard conditions of use. In addition to collecting and analyzing basic demographic information, the study presents data from the inaugural patient cohort permanently implanted at multiple European centers.
Results: A significant decrease in pain intensity was observed for overall back or leg pain scores (verbal numerical rating score [VNRS]) between baseline (mean ± standard error of the mean [SEM]; n = 135; 8.2 ± 0.1), 3 months (n = 93; 2.3 ± 0.2), 6 months (n = 82; 2.5 ± 0.3), and 12 months (n = 76; 2.5 ± 0.3). Comparison of overall pain relief (%) to the AVALON and EVOKE studies showed no significant differences at 3 and 12 months between the real-world data release (RWE; 71.3%; 69.6%) and the AVALON (71.2%; 73.6%) and EVOKE (78.1%; 76.7%) studies. Further investigation was undertaken to objectively characterize the physiological parameters of SCS therapy in this cohort using the metrics of percent time above ECAP threshold (%), dose ratio, and dose accuracy (µV), according to previously described methods. Results showed that a median of 90% (40.7-99.2) of stimuli were above the ECAP threshold, with a dose ratio of 1.3 (1.1-1.4) and dose accuracy of 4.4 µV (0.0-7.1), based on data from 236, 230, and 254 patients, respectively. Thus, across all three metrics, the majority of patients had objective therapy metrics corresponding to the highest levels of pain relief in previously reported studies (usage over threshold > 80%, dose ratio > 1.2, and error < 10 µV).
Conclusions: In conclusion, this study provides valuable insights into the real-world application of the ECAP-controlled CL-SCS system, highlighting its potential for maintaining effective pain relief and objective neurophysiological therapy metrics at levels seen in randomized control trials, and potential for quantifying patient burden associated with SCS system use via patient-device interaction metrics.
Clinical Trial Registration: In the Netherlands, the study is duly registered on the International Clinical Trials Registry Platform (Trial NL7889). In Germany, the study is duly registered as NCT05272137 and in the United Kingdom as ISCRTN27710516 and has been reviewed by the ethics committee in both countries.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje